Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Caroline O'Neil

Physician Assistant, Medical Pittsburgh, PA Physician Assistant

NPI 1710525258 CMS profile 11104992

300 Halket St Ste 1601, Pittsburgh, PA 15213

Open in the dashboard

General payments

$24,750

1,270 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Caroline O'Neil of Pittsburgh, PA is reported in the CMS Open Payments database as having received $24,750 across 1,270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $4,134 187
2023 General $7,821 348
2022 General $7,160 371
2021 General $5,635 364

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caroline O'Neil
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Caroline O'Neil were reported at $0. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Caroline O'Neil Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $5,635 $156 $41–$563 $132
2022 $7,160 $185 $55–$649 $149
2023 $7,821 $199 $58–$717 $160
2024 $4,134 $206 $62–$740 $164
2025 $0 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Amgen Inc. $3,962 190 payments
  2. AbbVie, Inc. $3,833 165 payments
  3. Janssen Biotech, Inc. $3,052 160 payments
  4. Daiichi Sankyo Inc. $1,511 76 payments
  5. Lilly USA, LLC $1,322 82 payments
  6. Pfizer Inc. $1,185 66 payments
  7. GlaxoSmithKline, LLC. $1,115 49 payments
  8. Mallinckrodt Hospital Products Inc. $1,080 50 payments
  9. AstraZeneca Pharmaceuticals LP $1,077 40 payments
  10. Novartis Pharmaceuticals Corporation $980 89 payments
  11. Other $5,636 303 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $24,718 1,267 payments
  2. Education $32 3 payments
Products named General payments · program years 2021–2024
  1. RINVOQ $3,274 130 payments
  2. TREMFYA $2,287 117 payments
  3. SIMPONI ARIA $1,957 119 payments
  4. Enbrel Inflammation $1,640 77 payments
  5. INJECTAFER $1,511 76 payments
  6. Otezla $1,418 53 payments
  7. TALTZ $1,204 80 payments
  8. Enbrel Inflammation $1,132 47 payments
  9. BENLYSTA $1,115 49 payments
  10. ACTHAR $1,080 50 payments
  11. Other $14,800 872 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

1,912

Median for Physician Assistant: 241

Drug cost

$985,345

Median for Physician Assistant: $4,110

Branded share of claims

24.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 27 $207,470
Humira(Cf) Pen Adalimumab Brand 24 $188,321
Rinvoq Upadacitinib Brand 20 $127,272
Taltz Autoinjector Ixekizumab Brand 18 $121,110
Orencia Clickject Abatacept Brand 15 $85,036
Evenity (2 Syringes) Romosozumab-Aqqg Brand 21 $51,605
Orencia Abatacept/Maltose Brand 12 $51,512
Tymlos Abaloparatide Brand 16 $51,308
Prolia Denosumab Brand 16 $27,934
Rasuvo Methotrexate/Pf Brand 39 $25,010

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$1,432

Of which drugs: $506

Medicare patients

18

Average age 73

Services billed

191

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Alzheimer's or dementia 0%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 136 $86

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 39 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$535 20 —
Enbrel
$334 — —
INJECTAFER
$293 — —
SAPHNELO
$274 — —
TREMFYA
$269 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 39 with Patron

Records

1,270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record